Researchers unveiled a ferritin‑based biomimetic platform (FACE) that augments CAR T cell avidity ex vivo and improves tumor cell engagement in refractory leukemia models without altering CAR constructs; the approach improved efficacy while lowering required cell doses and reduced cytokine risk in preclinical work. FACE is positioned as an off‑the‑shelf manufacturing supplement that can integrate into existing CAR T workflows. At the same time, the field continues to evaluate in‑vivo CAR T platforms that aim to engineer therapeutic T cells inside the patient, using viral or non‑viral delivery systems to simplify manufacturing and broaden access. Industry groups are investing in in‑vivo approaches despite scaling and specificity challenges; large pharmaceutical players are acquiring enabling platforms to secure rights to this potentially transformative delivery model. Named sources: Institute of Process Engineering/Cell paper describing FACE and industry reviews of in‑vivo CAR T strategies. For readers: FACE represents a manufacturing adjunct to boost cellular potency, while in‑vivo CAR T promises off‑the‑shelf administration by reprogramming cells inside patients — two distinct paths aiming to expand CAR T reach.